{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:42:28Z","timestamp":1777614148331,"version":"3.51.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T00:00:00Z","timestamp":1397692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11934-014-0415-4","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T04:07:13Z","timestamp":1397621233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Update on Medical Management of Peyronie\u2019s Disease"],"prefix":"10.1007","volume":"15","author":[{"given":"Ronny B. W.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Premsant","family":"Sangkum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J. G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,17]]},"reference":[{"key":"415_CR1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1464-410X.1996.14120.x","volume":"78","author":"WD Dunsmuir","year":"1996","unstructured":"Dunsmuir WD, Kirby R. Francois de LaPeyronie (1978\u20131747): the man and the disease he described. Br J Urol. 1996;78:613\u201322.","journal-title":"Br J Urol"},{"key":"415_CR2","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","volume":"5","author":"CJ Nelson","year":"2008","unstructured":"Nelson CJ, Diblasio C. The chronology of depression and distress in men with Peyronie disease. J Sex Med. 2008;5:1985\u201390.","journal-title":"J Sex Med"},{"key":"415_CR3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00003495-200767040-00004","volume":"67","author":"LW Trost","year":"2007","unstructured":"Trost LW, Gur S. Pharmacological management of Peyronie\u2019s disease. Drugs. 2007;67:527\u201345.","journal-title":"Drugs"},{"key":"415_CR4","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","volume":"6","author":"A Muller","year":"2009","unstructured":"Muller A, Mulhall J. Peyronie\u2019s disease intervention trials: methodological challenges and issues. J Sex Med. 2009;6:848\u201361.","journal-title":"J Sex Med"},{"key":"415_CR5","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0022-5347(01)64222-8","volume":"158","author":"JP Jarow","year":"1997","unstructured":"Jarow JP, Lowe F. Penile trauma: an etiologic factor in Peyronie disease and erectile dysfunction. J Urol. 1997;158:1388\u201390.","journal-title":"J Urol"},{"key":"415_CR6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0022-5347(01)68236-3","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka AI, Hassoba H. An animal model of Peyronie-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158:2284\u201390.","journal-title":"J Urol"},{"key":"415_CR7","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/S0022-5347(05)67616-1","volume":"163","author":"TJ Bivalacqua","year":"2000","unstructured":"Bivalacqua TJ, Diner E. A rat model of Peyronie disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol. 2000;163:1992\u20138.","journal-title":"J Urol"},{"key":"415_CR8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/niox.2001.0421","volume":"6","author":"MG Ferrini","year":"2002","unstructured":"Ferrini MG, Vernet D-C. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide. 2002;6:283\u201394.","journal-title":"Nitric Oxide"},{"key":"415_CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","volume":"2","author":"NF Gonzalez-Cadavid","year":"2005","unstructured":"Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie disease. Nat Clin Pract Urol. 2005;2:291\u20137.","journal-title":"Nat Clin Pract Urol"},{"key":"415_CR10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1743-6109.2007.00674.x","volume":"5","author":"AW Shindel","year":"2008","unstructured":"Shindel AW, Bullock T. Urologist practice patterns in the management of Peyronie\u2019s disease: a national wide survery. J Sex Med. 2008;5:954\u201364.","journal-title":"J Sex Med"},{"key":"415_CR11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00007611-194802000-00017","volume":"41","author":"WW Scott","year":"1948","unstructured":"Scott WW, Scardino P. A new concept in the treatment of Peyronie\u2019s disease. South Med J. 1948;41:173\u20137.","journal-title":"South Med J"},{"issue":"6","key":"415_CR12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1517\/14656566.2011.544252","volume":"12","author":"S Gur","year":"2011","unstructured":"Gur S, Limin M. Current status and new developments in Peyronie\u2019s disease: medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother. 2011;12(6):931\u201344.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"415_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ucl.2011.02.006","volume":"38","author":"SM Larsen","year":"2011","unstructured":"Larsen SM, Levine L. Peyronies disease: review of nonsurgical treatment options. Urol Clin N Am. 2011;38(2):195\u2013205.","journal-title":"Urol Clin N Am"},{"key":"415_CR14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini S. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo conrolled, randomized study. J Urol. 2007;178:1398\u2013403.","journal-title":"J Urol"},{"key":"415_CR15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1442-2042.2006.01270.x","volume":"13","author":"K Hashimoto","year":"2006","unstructured":"Hashimoto K, Hisasue S. Outcome analysis for conservative management of Peyronies disease. Int J Urol. 2006;13:244\u20137.","journal-title":"Int J Urol"},{"issue":"1","key":"415_CR16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","volume":"1","author":"G Paulis","year":"2013","unstructured":"Paulis G, Brancato T. Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: legend of reality? A controlled study of 70 cases. Andrology. 2013;1(1):120\u20138.","journal-title":"Andrology"},{"issue":"4","key":"415_CR17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2605.2011.01219.x","volume":"35","author":"G Paulis","year":"2012","unstructured":"Paulis G, D\u2019Ascenzo R. Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie\u2019s disease: a study of 151 cases. Int J Androl. 2012;35(4):521\u20137.","journal-title":"Int J Androl"},{"issue":"4","key":"415_CR18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2164\/jandrol.108.006221","volume":"30","author":"WJ Hellstrom","year":"2009","unstructured":"Hellstrom WJ. Medical management of Peyronie\u2019s disease. J Androl. 2009;30(4):397\u2013405.","journal-title":"J Androl"},{"key":"415_CR19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-5347(17)66108-1","volume":"81","author":"CJ Zarafonetis","year":"1959","unstructured":"Zarafonetis CJ, Horrax T. Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (potaba). J Urol. 1959;81:770\u20132.","journal-title":"J Urol"},{"key":"415_CR20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"W Weidner","year":"2005","unstructured":"Weidner W, Hauck E. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530\u20136.","journal-title":"Eur Urol"},{"issue":"2","key":"415_CR21","first-page":"2217","volume":"20","author":"J Stoevesandt","year":"2010","unstructured":"Stoevesandt J, K\u00fcrzinger N. Uro-dermatological problems of a construction worker: paraaminobenzoic acid as a systemic photosensitizer. Eur J Dermatol. 2010;20(2):2217\u20139.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"415_CR22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/187152812798889321","volume":"11","author":"G Paulis","year":"2012","unstructured":"Paulis G, Brancato T. Inflammatory mechanisms and oxidate stress in Peyronie\u2019s disease: therapeutic \u201crationale\u201d and related emerging treatment strategies. Inflamm Allergy Drug Targets. 2012;11(1):48\u201357.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"415_CR23","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","volume":"162","author":"C Teloken","year":"1999","unstructured":"Teloken C, Rhoden E. Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease. J Urol. 1999;162:2003\u20135.","journal-title":"J Urol"},{"key":"415_CR24","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/S0022-5347(05)68868-4","volume":"191","author":"AI El-Sakka","year":"1999","unstructured":"El-Sakka AI, Bakircioglu M. The effects of colchicine on a Peyronie\u2019s-like condition in an animal model. J Urol. 1999;191:1980\u20133.","journal-title":"J Urol"},{"key":"415_CR25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","volume":"44","author":"E Akkus","year":"1994","unstructured":"Akkus E et al. Is colchine effective in Peyronie\u2019s disease? A pilot study. Urology. 1994;44:291\u20136.","journal-title":"Urology"},{"issue":"3","key":"415_CR26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad MR et al. Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16(3):238\u201343.","journal-title":"Int J Impot Res"},{"issue":"6","key":"415_CR27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","volume":"91","author":"RM Prieto Castro","year":"2003","unstructured":"Prieto Castro RM, Leva Vallejo ME. Combined treatment with vitamin E and colchicine in the early stages of Peyronie\u2019s disease. BJU Int. 2003;91(6):522\u20134.","journal-title":"BJU Int"},{"issue":"5","key":"415_CR28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.acuro.2010.03.009","volume":"34","author":"JR Cortes-Gonzalez","year":"2010","unstructured":"Cortes-Gonzalez JR, Glina S. Conservative treatment of Peyronie\u2019s disease: colchicine vs cochicine plus vitamin E. Actas Urol Esp. 2010;34(5):444\u20139.","journal-title":"Actas Urol Esp"},{"key":"415_CR29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","volume":"88","author":"G Biagiotti","year":"2001","unstructured":"Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie\u2019s disease: a preliminary report. BJU Int. 2001;88:63\u20137.","journal-title":"BJU Int"},{"key":"415_CR30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1464-410X.2002.02738.x","volume":"89","author":"G Cavallini","year":"2002","unstructured":"Cavallini G, Biagiotti G. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie\u2019s disease. BJU Int. 2002;89:895.","journal-title":"BJU Int"},{"issue":"4","key":"415_CR31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","volume":"7","author":"NF Gonzalez-Cadavid","year":"2010","unstructured":"Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie\u2019s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7(4):215\u201321.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"415_CR32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/j.1743-6109.2011.02217.x","volume":"8","author":"E Chung","year":"2011","unstructured":"Chung E, Deyoung L. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472\u20137.","journal-title":"J Sex Med"},{"issue":"6","key":"415_CR33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/j.1743-6109.2010.01790.x","volume":"7","author":"AW Shindel","year":"2010","unstructured":"Shindel AW, Lin G. Pentoxifylline attenuates transforming growth factor- beta-1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracelluar matrix. J Sex Med. 2010;7(6):2077\u201385.","journal-title":"J Sex Med"},{"issue":"2","key":"415_CR34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","volume":"106","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR, Asgari M. A double-bind placebo-controlled study of the efficacy and safety of pentoxyfylline in early chronic Peyronie\u2019s disease. BJU Int. 2010;106(2):240\u20138.","journal-title":"BJU Int"},{"issue":"2","key":"415_CR35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/aja.2010.117","volume":"13","author":"JF Smith","year":"2011","unstructured":"Smith JF, Shindel A. Pentoxifylline treatment and penile calcifications in men with Peyronie\u2019s disease. Asian J Androl. 2011;13(2):322\u20135.","journal-title":"Asian J Androl"},{"issue":"6","key":"415_CR36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1743-6109.2009.01235.x","volume":"6","author":"MR Safarinejad","year":"2009","unstructured":"Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie\u2019s disease. A prospective, randomized, double-blind placebo-controlled study. J Sex Med. 2009;6(6):1743\u201354.","journal-title":"J Sex Med"},{"issue":"5","key":"415_CR37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ijir.2010.20","volume":"22","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chornic Peyronie\u2019s disease: a double-blind, placebo-controlled study. Int J Impot Res. 2010;22(5):298\u2013309.","journal-title":"Int J Impot Res"},{"key":"415_CR38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch 3rd","year":"2007","unstructured":"Fitch 3rd WP, Easterling W. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie disease\u2014a placebo-controlled pilot study. J Sex Med. 2007;4:477\u201384.","journal-title":"J Sex Med"},{"key":"415_CR39","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/S0022-5347(05)64173-0","volume":"168","author":"DJ Martin","year":"2002","unstructured":"Martin DJ, Badwan K. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168:2483\u20135.","journal-title":"J Urol"},{"key":"415_CR40","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/10611860903089750","volume":"17","author":"A Sieg","year":"2009","unstructured":"Sieg A, Wascotte V. Diagnostic and therapeutic applications of iontophoresis. J Drug Target. 2009;17:690\u2013700.","journal-title":"J Drug Target"},{"key":"415_CR41","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0022-5347(17)63139-2","volume":"97","author":"SH Rothfeld","year":"1967","unstructured":"Rothfeld SH, Murray W. The treatment of Peyronie disease by iontophoresis of C21 esterified glucocortocoids. J Urol. 1967;97:874\u20135.","journal-title":"J Urol"},{"key":"415_CR42","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","volume":"171","author":"SM Stasi Di","year":"2004","unstructured":"Di Stasi SM, Giannantoni A. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie disease. J Urol. 2004;171:1605\u20138.","journal-title":"J Urol"},{"key":"415_CR43","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"JM Greenfield","year":"2007","unstructured":"Greenfield JM, Shah S. Verapamil versus saline in electromotive drug administration for Peyronie disease: a double- blind, placebo controlled trial. J Urol. 2007;177:972\u20135.","journal-title":"J Urol"},{"key":"415_CR44","first-page":"32","volume":"20","author":"H Bodner","year":"1953","unstructured":"Bodner H, Howard A. Peyronie disease; cortisone- hyaluronidase-hydrocortisone therapy. Trans West Sect Am Urol Assoc. 1953;20:32\u20135.","journal-title":"Trans West Sect Am Urol Assoc"},{"key":"415_CR45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-5347(17)62993-8","volume":"97","author":"PN Desanctis","year":"1967","unstructured":"Desanctis PN, Furey C. Steroid injection therapy for Peyronie disease: a 10-year summary and review of 38 cases. J Urol. 1967;97:114\u20136.","journal-title":"J Urol"},{"key":"415_CR46","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-5347(17)67169-6","volume":"114","author":"CC Winter","year":"1975","unstructured":"Winter CC, Khanna R. Peyronie disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114:898\u2013900.","journal-title":"J Urol"},{"key":"415_CR47","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01781.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N. The medical management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359\u201374.","journal-title":"J Sex Med"},{"key":"415_CR48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1743-6109.2004.10116.x","volume":"1","author":"J Pryor","year":"2004","unstructured":"Pryor J, Akkus E. Peyronie\u2019s disease. J Sex Med. 2004;1:110\u20135.","journal-title":"J Sex Med"},{"key":"415_CR49","first-page":"6","volume":"1","author":"TF Lue","year":"2004","unstructured":"Lue TF, Giuliano F. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004;1:6\u201323.","journal-title":"J Sex Med"},{"key":"415_CR50","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0022-5347(17)35291-6","volume":"151","author":"LA Levine","year":"1994","unstructured":"Levine LA, Merrick P. Intralesional verapamil injection for the treatment of Peyronie\u2019s disease. J Urol. 1994;151:1522\u20134.","journal-title":"J Urol"},{"key":"415_CR51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine LA, Goldman K. Experience with intra-plaque injection of verapamil for Peyronie\u2019s disease. J Urol. 2002;168:621\u20136.","journal-title":"J Urol"},{"key":"415_CR52","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eururo.2006.10.042","volume":"51","author":"S Russell","year":"2007","unstructured":"Russell S, Steers W. Systematic evidence-based analysis of plaque injection therapy for Peyronie\u2019s disease. Eur Urol. 2007;51:640\u20137.","journal-title":"Eur Urol"},{"key":"415_CR53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","volume":"51","author":"J Rehman","year":"1998","unstructured":"Rehman J, Benet A. Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study. Urology. 1998;51:620\u20136.","journal-title":"Urology"},{"key":"415_CR54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi M, Haghpanah A. Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo- controlled study. Int Urol Nephrol. 2009;41:467\u201371.","journal-title":"Int Urol Nephrol"},{"key":"415_CR55","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","volume":"7","author":"J Soh","year":"2010","unstructured":"Soh J, Kawauchi A. Nicardipine vs. saline injection as treatment for Peyronie disease: a prospective, randomized, single-blind trial. J Sex Med. 2010;7:3743\u20139.","journal-title":"J Sex Med"},{"key":"415_CR56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365599109024539","volume":"25","author":"MR Duncan","year":"1991","unstructured":"Duncan MR, Berman B. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25:89\u201394.","journal-title":"Scand J Urol Nephrol"},{"key":"415_CR57","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/j.1939-4640.1999.tb02539.x","volume":"20","author":"S Ahuja","year":"1999","unstructured":"Ahuja S, Bivalacqua T. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie\u2019s disease. J Androl. 1999;20:444\u20138.","journal-title":"J Androl"},{"key":"415_CR58","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1464-410x.2001.02139.x","volume":"87","author":"M Brake","year":"2001","unstructured":"Brake M, Loertzer H. Treatment of Peyronie\u2019s disease with local interferon-alpha 2b. BJU Int. 2001;87:654\u20137.","journal-title":"BJU Int"},{"key":"415_CR59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom WJ, Kendirci M. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie disease. J Urol. 2006;176:394\u20138.","journal-title":"J Urol"},{"key":"415_CR60","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","volume":"67","author":"T Inal","year":"2006","unstructured":"Inal T, Tokatli Z. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie disease: a randomized and prospective study. Urology. 2006;67:1038\u201342.","journal-title":"Urology"},{"key":"415_CR61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2164\/jandrol.110.010561","volume":"33","author":"AJ Schaeffer","year":"2012","unstructured":"Schaeffer AJ, Burnett A. Nonsurgical interventions for Peyronie\u2019s disease: 2011 update. J Androl. 2012;33:3\u201314.","journal-title":"J Androl"},{"key":"415_CR62","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJMoa0810866","volume":"361","author":"LC Hurst","year":"2009","unstructured":"Hurst LC, Badalamente M. Injectable collagenase clostridium histolyticum for Dupuytren\u2019s contracture. N Engl J Med. 2009;361:968\u201379.","journal-title":"N Engl J Med"},{"key":"415_CR63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard MK, James K. Collagenase versus placebo in the treatment of Peyronie disease: a double-blind study. J Urol. 1993;149:56\u20138.","journal-title":"J Urol"},{"key":"415_CR64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","volume":"5","author":"G Jordan","year":"2008","unstructured":"Jordan G. The use of intralesional clostridial collagenase injection therapy for Peyronie disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5:180\u20137.","journal-title":"J Sex Med"},{"key":"415_CR65","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz L. Phase 2b study of clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie\u2019s disease. J Urol. 2012;187:2268.","journal-title":"J Urol"},{"key":"415_CR66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol"},{"key":"415_CR67","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00005392-199502000-00023","volume":"153","author":"SJ Hall","year":"1995","unstructured":"Hall SJ, Basile G. Extensive corporeal fibrosis after penile irradiation. J Urol. 1995;153:372\u20137.","journal-title":"J Urol"},{"issue":"Pt 1","key":"415_CR68","first-page":"297","volume":"23","author":"LF Fajardo","year":"1998","unstructured":"Fajardo LF, Berthrong M. Vascular lesions following radiation. Pathol Annu. 1998;23(Pt 1):297\u2013330.","journal-title":"Pathol Annu"},{"key":"415_CR69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/14737167.4.2.235","volume":"4","author":"L Incrocci","year":"2004","unstructured":"Incrocci L. Radiotherapeutic treatment of Peyronie\u2019s disease. Expert Rev Pharmacoecon Outcomes Res. 2004;4:235\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"415_CR70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0167-8140(99)00066-3","volume":"51","author":"KR Trott","year":"1999","unstructured":"Trott KR, Kamprad F. Radiobiological mechanisms of anti- inflammatory radiotherapy. Radiother Oncol. 1999;51:197\u2013203.","journal-title":"Radiother Oncol"},{"key":"415_CR71","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1743-6109.2012.02677.x","volume":"9","author":"JP Mulhall","year":"2012","unstructured":"Mulhall JP, Hall M. Radiation therapy in Peyronie\u2019s disease. J Sex Med. 2012;9:1435\u201341.","journal-title":"J Sex Med"},{"key":"415_CR72","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/end.1999.13.549","volume":"13","author":"Y Abdel-Salam","year":"1999","unstructured":"Abdel-Salam Y, Budair Z. Treatment of Peyronie disease by extracorporeal shockwave therapy: evaluation of our preliminary results. J Endourol. 1999;13:549\u201352.","journal-title":"J Endourol"},{"key":"415_CR73","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1464-410x.2001.02194.x","volume":"87","author":"R Hamm","year":"2001","unstructured":"Hamm R, Mclarty E. Peyronie disease\u2014the Plymouth experience of extracorporeal shockwave treatment. BJU Int. 2001;87:849\u201352.","journal-title":"BJU Int"},{"key":"415_CR74","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie disease. Eur Urol. 2009;56:363\u20139.","journal-title":"Eur Urol"},{"key":"415_CR75","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","volume":"106","author":"S Chitale","year":"2010","unstructured":"Chitale S, Morsey M. Limited shock wave therapy vs sham treatment in men with Peyronie disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352\u20136.","journal-title":"BJU Int"},{"key":"415_CR76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1302\/0301-620X.80B1.8019","volume":"80","author":"N Citron","year":"1998","unstructured":"Citron N, Messina J. The use of skeletal traction in the treatment of severe primary Dupuytren\u2019s disease. J Bone Joint Surg (Br). 1998;80:126\u20139.","journal-title":"J Bone Joint Surg (Br)"},{"key":"415_CR77","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/0266-7681(94)90220-8","volume":"19","author":"AJ Bailey","year":"1994","unstructured":"Bailey AJ, Tarlton J. The continuous elongation technique for severe Dupuytren\u2019s disease. J Hand Surg (Br). 1994;19:522\u20137.","journal-title":"J Hand Surg (Br)"},{"key":"415_CR78","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1743-6109.2008.00814.x","volume":"5","author":"LA Levine","year":"2008","unstructured":"Levine LA, Newell M. Penile traction therapy for treatment of Peyronie disease: a single-center pilot study. J Sex Med. 2008;5:1468\u201373.","journal-title":"J Sex Med"},{"key":"415_CR79","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1743-6109.2008.01108.x","volume":"6","author":"P Gontero","year":"2009","unstructured":"Gontero P, Di Marco M. Use of penile extender device in the treatment of penile curvature as a result of Peyronie disease. Results of a phase II prospective study. J Sex Med. 2009;6:558\u201366.","journal-title":"J Sex Med"},{"key":"415_CR80","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1743-6109.2011.02561.x","volume":"9","author":"L Ferretti","year":"2012","unstructured":"Ferretti L, Giuliani M. Tissue engineering for penile surgery: comparative study of noncellular and cell-seeded synthetic grafts for tunica albuginea replacement. J Sex Med. 2012;9:625\u201331.","journal-title":"J Sex Med"},{"key":"415_CR81","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1111\/j.1743-6109.2011.02374.x","volume":"8","author":"A Imbeault","year":"2011","unstructured":"Imbeault A, Bernard G. Surgical option for the correction of Peyronie\u2019s disease: an autologous tissue-engineered endothelialized graft. J Sex Med. 2011;8:3227\u201335.","journal-title":"J Sex Med"},{"key":"415_CR82","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1089\/scd.2012.0176","volume":"21","author":"CS Lin","year":"2012","unstructured":"Lin CS. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Stem Cells Dev. 2012;21:2770\u20138.","journal-title":"Stem Cells Dev"},{"key":"415_CR83","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1743-6109.2009.01697.x","volume":"7","author":"YC Huang","year":"2010","unstructured":"Huang YC. The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. J Sex Med. 2010;7:1391\u2013400.","journal-title":"J Sex Med"},{"key":"415_CR84","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2012.09.034","volume":"63","author":"F Castiglione","year":"2013","unstructured":"Castiglione F, Hedlund P. Intratunical injection of human adipose tisse-derived stem cells prevents fibrosis and is associated with improved erectile functionin a rat model of Peyronie\u2019s disease. Eur Urol. 2013;63:551\u201360.","journal-title":"Eur Urol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-014-0415-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-014-0415-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-014-0415-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T22:53:54Z","timestamp":1716677634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-014-0415-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,17]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1007\/s11934-014-0415-4","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,17]]},"article-number":"415"}}